This study is a real-world study. we collected patients with advanced HER2-negative breast cancer previously treated with antibody-drug conjugates, and received eribulin mesylate-based therapy post-ADC. We retrospectively collect the data on previous systemic treatment, and prospectively collect the treatment data of the therapeutic regimens based on eribulin mesylate.
At least 18 years old;
Inoperable locally advanced or metastatic breast cancer;
Planning to use a single-agent or combination treatment regimen based on eribulin;
HER2 negative (IHC 0,+, or ++ but ISH negative);
HER2-positive tumors
The hormone receptor status is unknown;
Patients who have received eribulin treatment before;
Those who have had other malignant tumors within the past 5 years (excluding the following situations: cured skin basal cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma; second primary cancer that has been cured and has no recurrence within 5 years; subjects who have clearly identified the origin of the metastatic lesion as being from a certain primary tumor);
Advanced HER2-negative breast cancer patients previously treated with ADC
Cohort
Prospective
Not listed
Progression-Free Survival (PFS)
the period from the start of eribulin mesylate-based therapy treatment until the disease progress or death from any cause, whichever occurred first
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
